Drugs / 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04016129 | Jul 2025 → Jul 2028 expected | B-cell acute lymphoblastic leukemia | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04016129 ↗ |
| Modality | Cell therapy | “one or multiple non-CD19 targeting CAR-T cells” NCT04016129 ↗ |